Evaluation of EVT401, a P2X7 receptor antagonist, in healthy Chinese participants: a first-in-human, double-blind, randomized, placebo-controlled, dose-escalation trial.
Haimei Xu, Liming Chen, Haiyan Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I, randomized, double-blind, placebo-controlled dose-escalation trial evaluated oral EVT401, a P2X7 receptor antagonist, in healthy Chinese participants aged 18 to 50 years. Across single-dose, food-effect, and multiple-dose studies, 101 participants were enrolled. The trial assessed safety, tolerability, pharmacokinetics, and exploratory immune effects. Only a few mild, transient adverse events were reported, with no serious adverse events. Pharmacokinetics were nonlinear; a high-fat meal increased absorption and systemic exposure. Exploratory findings suggested an anti-inflammatory trend, including increased regulatory T cells and reduced helper T cells.
Key findings
- Among 101 participants, only a few mild, transient adverse events occurred, and no serious adverse events were observed.
- Mean half-lives ranged from 12.7 to 28.3 h, and dose-exposure analysis indicated nonlinear pharmacokinetics.
- A high-fat meal increased EVT401 absorption and systemic exposure.
- Exploratory pharmacodynamic findings suggested upregulation of regulatory T cells and suppression of helper T cells.
Why it matters
P2X7 receptor inhibition is being explored as a way to modulate inflammation relevant to rheumatoid arthritis. These first-in-human findings provide early information on EVT401’s tolerability, exposure, and potential immune effects in healthy participants, helping characterize the compound for further study. The exploratory immune findings are not evidence of clinical benefit in people with rheumatoid arthritis.
What to keep in mind
The trial involved healthy participants, not patients with rheumatoid arthritis; its pharmacodynamic outcomes were exploratory and do not establish therapeutic efficacy.